RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Direct Answers, Graded by Evidence
The questions readers most often bring to CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, answered against the actual published record.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), chemically modified to resist enzymatic breakdown and, in its long-acting DAC form, to bind circulating albumin so a single dose keeps growth hormone and IGF-1 elevated for days rather than minutes [4]. It is not approved for human use anywhere and is sold only as a research chemical.
Is CJC-1295 safe?
No dedicated human safety trial of CJC-1295 exists, so 'safe' cannot be answered with clinical-trial confidence either way. What is documented is that growth-hormone-axis stimulation carries known, mechanism-based cautions — theoretical cancer risk via IGF-1 elevation, fluid retention, and effects on insulin sensitivity — alongside a discontinued original development program and an FDA-flagged immunogenicity concern for long-acting GHRH analogs as a class [1]. The honest answer is that CJC-1295's safety, at the doses and durations used in research-community protocols, has simply not been tested in a controlled human trial.
What is ipamorelin?
Ipamorelin is a five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering growth-hormone release without meaningfully raising cortisol or prolactin — its defining pharmacological feature relative to older growth-hormone-releasing peptides. It has never been approved as a drug; its only human efficacy trial, testing it for postoperative gut recovery, did not meet its primary endpoint [8].
What are the risks of ipamorelin?
The documented risks are mechanistic rather than drawn from a dedicated long-term ipamorelin safety trial, because none exists. Growth-hormone elevation carries a theoretical cancer-risk concern via IGF-1. A structurally related (not identical) ghrelin-receptor agonist produced dose-dependent heart muscle damage in a 28-day rat study, which keeps chronic cardiovascular safety an open question for this receptor class [7]. Ipamorelin's own direct effect on pancreatic insulin release in animal tissue, combined with growth hormone's glucose-sparing action, makes its net effect on blood sugar difficult to predict in anyone with diabetes or insulin resistance.
What is KPV peptide used for?
In published research, KPV has been studied exclusively for reducing intestinal inflammation in mouse models of colitis, where it consistently lowers inflammatory cytokines and speeds recovery [11][13][14]. It has never been tested in a human clinical trial for this or any other use, so 'used for' should be read as 'studied for in animals,' not as an established human application.
What does retatrutide do?
Retatrutide activates three receptors at once — GLP-1, GIP, and glucagon — combining appetite suppression with a proposed increase in energy expenditure from the glucagon-receptor component. In a Phase 2 obesity trial, the highest dose produced roughly 24% mean body-weight loss over 48 weeks versus about 2% with placebo [19]. It remains investigational and unapproved by any regulator.
Is retatrutide FDA approved?
No. As of this writing, retatrutide has not been approved by the FDA or any other regulatory agency; it is in Phase 3 clinical trials. All efficacy and safety data currently available come from Phase 1 and Phase 2 studies, and material sold outside those trials as research-grade retatrutide cannot be verified for identity or purity [16][19].
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist — an engineered analog of a natural gut hormone — approved by the FDA for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, a form of fatty liver disease. It is the only compound on this desk that is a prescription medicine rather than a research chemical.
What is semaglutide used for?
Its approved uses are lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management, reducing the risk of major cardiovascular events in people with established cardiovascular disease and overweight or obesity [23], and treating metabolic dysfunction-associated steatohepatitis. It has also reduced major kidney-disease events in people with type 2 diabetes and chronic kidney disease in a dedicated outcomes trial [22].
How does semaglutide work for weight loss?
Semaglutide reaches appetite-regulating circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing neurons that drive hunger, without measurably lowering the body's baseline energy expenditure [26]. In its largest weight-management trial, that translated into a mean 14.9% body-weight reduction over 68 weeks versus 2.4% with placebo [24] — though in a later head-to-head trial, tirzepatide outperformed it [21].
How much CJC-1295 should I take?
This desk does not answer that question, and no page here will. CJC-1295 is not an approved drug, no clinical dosing guideline exists for it, and there is no controlled human efficacy trial establishing what any dose actually accomplishes. The human pharmacokinetic studies that do exist used specific research doses — 30 to 90 micrograms per kilogram — under clinical supervision to measure hormone levels, not to establish a safe or effective dose for self-administration [4][5]. A dosing question about an unapproved research chemical is a question for a qualified physician or toxicologist, not a website.
How to reconstitute retatrutide?
This desk does not provide reconstitution, handling, or administration instructions for any compound, and retatrutide is not approved for use outside registered clinical trials in the first place. Retatrutide obtained through research-chemical channels is not manufactured, tested, or verified to pharmaceutical standards, and there is no regulator-reviewed guidance for handling it outside a trial protocol. Questions about administering an investigational drug belong with the clinical trial sponsoring it, not with an independent literature digest.